Akari Therapeutics Plc (AKTX) Q2 2024 Earnings Report

Akari Therapeutics reported QQ2 2024 results for the quarter ended June 30, 2024, with no revenue and continuing losses driven by research and development and general administrative expenses. Reported operating loss of approximately $7.445 million and net loss of about $7.556 million, translating to an earnings per share of roughly -$0.80 on 9.418 million weighted-average shares. Management did not provide formal forward-looking revenue guidance in the filing, underscoring the company’s status as a clinical-stage biotechnology company reliant on external financing and successful clinical readouts to reset growth expectations.

The quarterly cash flow showed a heavy burn from operations of about $4.89 million, offset by net cash inflows from financing activities of approximately $7.76 million, resulting in a modest net cash increase of about $2.87 million. At quarter-end, Akari carried roughly $4.18 million in cash and cash equivalents against current liabilities of about $8.78 million and total liabilities of $8.78 million, yielding a current ratio of 0.58 and a cash-based liquidity position that signals meaningful dilution or external funding needs to continue operations beyond the near term. The balance sheet also shows negative stockholders’ equity of about $3.70 million and a sizable accumulated deficit, reflecting accumulated clinical-stage investment with limited-to-no current product revenue. Given these dynamics, the near-term investment thesis hinges on successful clinical progress for nomacopan (AKTX’s lead candidate) and the company’s ability to secure additional capital or strategic partnerships to extend runway and advance key trials.